Inhibiting glutamine metabolism to treat tuberculosis and HIV
Glutamine metabolism inhibitors for TB and TB-HIV: dual action as host-directed therapies with antibacterial activity
This study is looking at a new treatment that uses special drugs to help boost the immune system's ability to fight both tuberculosis (TB) and HIV by targeting certain cells that weaken the immune response, and it's designed for people who are dealing with these infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Johns Hopkins University NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project ID | NIH-10892151 on NIH RePORTER |
What this research studies
This research investigates the use of glutamine metabolism inhibitors as a dual-action therapy for tuberculosis (TB) and HIV. By targeting myeloid-derived suppressor cells (MDSCs), which suppress immune responses, the study aims to enhance the body's ability to fight these infections. The approach involves evaluating novel inhibitors that have shown promise in animal models for their effectiveness against TB while also being safe for potential human use. The collaboration between experts in tumor immunology, chemistry, and TB aims to translate these findings into effective treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with tuberculosis or HIV, particularly those who may benefit from enhanced immune responses.
Not a fit: Patients who do not have tuberculosis or HIV, or those with other unrelated health conditions, may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that improve immune responses in patients with TB and HIV, potentially reducing disease severity and improving outcomes.
How similar studies have performed: Previous research has shown success with similar approaches in animal models, indicating potential for effective treatments in humans.
Where this research is happening
Baltimore, United States
- Johns Hopkins University — Baltimore, United States (Active)
Researchers
- Principal investigator: Bishai, William Ramses — Johns Hopkins University
- Study coordinator: Bishai, William Ramses
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.